Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine'It's gone 5 years or so... (Duh..? 5 years, really? 🥴) since everyone was talking about COVID-19 pandemic, vaccines, "world will never be the same again", and so on.
- And now?..
- It's gone. It's absolutely gone..! Since nothing last forever and no one should chase a feather, or dust in the wind.
This is why we at our 💖Super-Duper Beloved @PandorraResearch Team decided to build this idea, as a educational idea to learn, even this story is about single Moderna stock, and we have reasonable considerations about fundamental, technical and price movement perspectives.
Well.. Let's the story begin...
Over the past few years, Moderna's stock has experienced a significant decline, primarily due to several key factors.
Here's a detailed explanation of why Moderna's stock has been moving downward:
1. Declining Demand for COVID-19 Vaccine
The primary reason for Moderna's stock decline is the waning demand for COVID-19 vaccines. During the pandemic, Moderna's mRNA-based vaccine was one of the first and most widely used, leading to a surge in sales and profitability. However, as the pandemic transitioned into an endemic phase, demand for vaccines decreased substantially. This shift has resulted in declining sales for Moderna, impacting its revenue and profitability.
2. Sales Guidance and Performance
In recent years, Moderna has faced challenges in meeting sales expectations. For instance, in 2025, the company forecasted sales between $1.5 billion and $2.5 billion, which was significantly lower than analysts' expectations of around $2.9 billion. This discrepancy led to a sharp decline in stock prices as investors became increasingly pessimistic about the company's future growth prospects.
3. Cost-Cutting Measures
To mitigate the impact of declining sales, Moderna has implemented cost-cutting measures. The company plans to reduce its cash operating costs by $1 billion in 2025 and an additional $500 million in 2026. While these efforts aim to improve profitability, they also reflect the challenges Moderna faces in maintaining its financial health without strong vaccine sales.
4. Competition in New Market s
Moderna is expanding into new markets, such as the respiratory syncytial virus (RSV) vaccine space, with its product mResvia. However, this market is highly competitive, with established players like Pfizer and GSK already present. The competition and uncertainty about market share have contributed to investor skepticism about Moderna's ability to drive growth through new products.
5. Delayed Break-Even Point
Initially, Moderna aimed to break even on an operating cash cost basis by 2026. However, this goal has been pushed back to 2028, indicating a slower-than-expected transition to profitability. This delay has further eroded investor confidence in the company's ability to execute its strategic plans effectively.
6. Valuation and Market Performance
Moderna's stock has underperformed both the industry and the broader market. The stock trades below its 200-day and 50-day moving averages, reflecting a lack of momentum. Additionally, Moderna's price-to-sales ratio is lower than the industry average, which might suggest undervaluation but also indicates a lack of investor enthusiasm for the stock.
7. Analyst Sentiment and Profitability Forecasts
Analysts have become increasingly pessimistic about Moderna's prospects, with many not expecting the company to turn profitable again until at least 2029. This negative outlook has contributed to the downward pressure on the stock. Furthermore, estimates for loss per share have increased, reinforcing the bearish sentiment among investors.
In summary, Moderna's stock decline is primarily driven by declining vaccine demand, missed sales expectations, increased competition in new markets, delayed profitability, and negative analyst sentiment. While the company is taking steps to adapt to these challenges, the path to recovery remains uncertain, contributing to ongoing investor skepticism.
--
Best 'No more Covid' wishes,
@PandorraResearch Team 😎
